Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Emerging Strategies to Optimize Therapeutic Benefit in GI and Lung Cancers: Lung Updates (23 mins)
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 28, 2020 Expiration: August 27, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an independent grant from
Helsinn Healthcare SA
person default
Mary Jo Fidler, MD
John L. Marshall, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Integrate new and emerging practice-changing therapeutic strategies into the care of patients with advanced gastrointestinal and lung malignancies to optimize clinical outcomes
  • Implement palliative care measures in concert with anticancer therapies to improve quality of live and survival in patients with advanced GI and lung malignancies
  • Proactively manage cancer-related anorexia and cachexia in patients with advanced GI and lung cancers to enable patients to receive maximal benefit from anticancer therapies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Mary Jo Fidler, MD

Associate Professor
Hematology-Oncology
Rush University Medical Center
Chicago, Illinois

Mary Jo Fidler, MD, has disclosed that she has received consulting fees from AstraZeneca and G1 Therapeutics, funds for research support from Biodesix and Pfizer, and fees for non-CME/CE services from AstraZeneca.
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees and fees for non-CME/CE services from Amgen, Bayer, Celgene, Genentech, Merck, and Taiho and salary from Caris and Indivumed.

Staff

Colleen Heffner, PharmD
Colleen Heffner has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with advanced lung and gastrointestinal cancers.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to apply the latest treatment approaches toward the optimal care of patients with advanced gastrointestinal and lung cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 28, 2020, through August 27, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Emerging Strategies to Optimize Therapeutic Benefit in GI and Lung Cancers: Lung Updates (23 mins)
  • CME

Mary Jo Fidler, MD, discusses key data in lung malignancies from ASCO 2020 and optimization of therapeutic benefit through management of cancer cachexia syndrome.
person default
Mary Jo Fidler, MD
John L. Marshall, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 28, 2020 Expiration: August 27, 2021

This program is divided into several short segments which you can step through using the Video Chapters widget.

Related Content

Interactive algorithm tool with NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities v1.2020, from CCO

Released: October 16, 2020

In this slideset from Clinical Care Options (CCO), Edward S. Kim, MD, FACP offers insight on using biomarkers for optimal therapy selection in NSCLC

Edward S. Kim, MD, FACP Released: October 15, 2020

In this slideset from Clinical Care Options (CCO), Sandip P. Patel, MD offers insight on therapeutic agents directed to emerging biomarkers in NSCLC

Sandip P. Patel, MD Released: October 15, 2020

Clinical commentary by Dr. Taofeek K. Owonikoko on frontline immunotherapy combinations for extensive-stage SCLC from Clinical Care Options (CCO)

Taofeek K. Owonikoko, MD, PhD Released: October 13, 2020

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an independent grant from
Helsinn Healthcare SA

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue